The Use of Hormone Replacement Therapy in Women Previously Treated for Breast Cancer

  • John A. Eden
  • Barry G. Wren
Conference paper


The postmenopausal woman who has had breast cancer presents the clinician with special difficulties. Most are unhappy to prescribe hormone replacement therapy (HRT) for these women for fear that HRT may stimulate their cancer. However, premenopausal women who have had early stage breast cancer are usually permitted to produce their own endogenous estrogen (1). Screening programs are detecting an increased number of early stage breast cancers and so many women may survive the tumor only to die of a cardiovascular disease or osteoporotic fracture. A number of lifestyle changes and non-sex hormone treatments are now available to reduce the risk of cardiovascular disease and osteoporotic fractures. Tamoxifen usage may also reduce the risk of heart disease and fractures but this drug is known to aggravate hot flashes and is associated with potentially serious problems including an increased risk of endometrial cancer (2). A small number of menopausal women (10–20%) will suffer severe debilitating menopausal symptoms, particularly hot flashes. For these women, life is unbearable. Quality of life is an important issue for women who have had cancer, so it is important for physicians involved in the care of such patients that treatment strategies are developed to deal with these symptoms. HRT includes a number of different sex hormone combinations of estrogen, progestins and sometimes androgens. Epidemiological studies have demonstrated small but significant differences in breast cancer risk associated with different types of estrogen (3, 4) and different combinations of progestin with estrogen (5). It is also likely that androgens will influence breast cancer risk (6, 7).


Breast Cancer Breast Cancer Risk Hormone Replacement Therapy Early Stage Breast Cancer Estrogen Replacement Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Creasman WT (1991) Estrogen replacement therapy: is previously treated cancer a contraindication? Obstet Gynecol 77:308–12.PubMedCrossRefGoogle Scholar
  2. 2.
    Early Breast Cancer Trialists’ Collaborative Group (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 319:1681–1692.CrossRefGoogle Scholar
  3. 3.
    Dupont WD, Page DL (1991) Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 151:67–72.PubMedCrossRefGoogle Scholar
  4. 4.
    Steinberg KK Thacker SB, Smith SJ, et al. (1991) A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265:1985–1990.PubMedCrossRefGoogle Scholar
  5. 5.
    Persson I, Yuen J, Bergkvist L, et al. (1992) Combined oestrogen-progestogen replacement and breast cancer risk. Lancet 340:1044.PubMedCrossRefGoogle Scholar
  6. 6.
    Blankenstein MA, Szymczak J, Daroszewski J, et al. (1992) Estrogens in plasma and fatty tissue from breast cancer patients and women undergoing surgery for non-oncological reasons. Gynecol Endocrinol 6:13–17.PubMedCrossRefGoogle Scholar
  7. 7.
    Gordon GB, Bush TL, Helzlsouer KJ, et al. (1990) Serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate and risk of postmenopausal breast cancer. Cancer Res 50:3859–62.PubMedGoogle Scholar
  8. 8.
    Clarke CL, Sutherland RL (1990) Progestin regulation of cellular proliferation. Endocrine Rev 11:266–301CrossRefGoogle Scholar
  9. 9.
    Anderson TJ, Battersby S (1989) The involvement of oestrogen in the development and function of the normal breast: histological evidence. In: Beck JS, editor. Oestrogen and the human breast. Royal Society of Edinburgh 23–32.Google Scholar
  10. 10.
    Rose C, Mouridsen M (1989) Endocrine management of advanced breast cancer. Horm Res 32: 189–97.PubMedCrossRefGoogle Scholar
  11. 11.
    Eden J A (1992) Oestrogen and the breast -1. Myths about oestrogen and breast cancer. Med J Aust 157:175–7.PubMedGoogle Scholar
  12. 12.
    Ewertz M. (1988) Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 42:832–838.PubMedCrossRefGoogle Scholar
  13. 13.
    Eden J A, Bush T, Nand S, Wren B G (1994) The Royal Hospital for Women Breast Cancer Study — A Case controlled study of combined continuous oestrogen progestogen replacement therapy amongst women with a personal history of breast cancer. Med J Aust. Submitted.Google Scholar
  14. 14.
    Haddow A, Watkinson JM, Paterson E (1944) Influence of synthetic oestrogens upon advanced malignant disease. Brit Med J Sept 23:393–98.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1996

Authors and Affiliations

  • John A. Eden
  • Barry G. Wren

There are no affiliations available

Personalised recommendations